Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes

Table 3 Percent of patients with RTOG grades 0-2 gastrointestinal (GI) and genitourinary (GU) toxicity

Toxicity	Grade	Months post treatment
		During SBRT	1	4	7-12	13-18
		50	50	46	41	36
GI	0	84%	88%	100%	100%	100%
	1	16%	8% (6%)^a	0	0	0
	2	0	4% (4%)^a	0	0	0
GU	0	38%	44%	63%	71%	75%
	1	32%	26% (4%)^a	20%	17%	14%
	2	30%	30% (12%)^a	17%	12%	11%

^aPercent in parentheses at one-month post treatment represents patients that were asymptomatic during SBRT but developed toxicity during the 4 weeks after completing radiotherapy

ISSN: 1748-717X